Want to see NCEL full AI Analyst Report?
NCEL Stock Chart & Stats
$3.26
--
Market closed
$3.26
--
Day’s Range― - ―
52-Week Range$1.83 - $26.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)320.89K
Market Cap
$17.44M
Enterprise Value-$1.65M
Total Cash (Recent Filing)$2.20M
Total Debt (Recent Filing)$355.00K
Price to Earnings (P/E)―
Beta1.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,345,184
10 Day Avg. Volume34,320
30 Day Avg. Volume320,894
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.63
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit833.27
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$23.00Price Target Upside605.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA-aligned Development PathwayRegulatory alignment on manufacturing, preclinical work and trial design reduces uncertainty around the next development stage. It gives NewcelX a clearer path toward an IND submission and potential first-in-human testing.
Experienced Scientific LeadershipAdding a recognized transplantation expert can strengthen clinical translation, trial planning and credibility with partners. His expertise supports NewcelX’s stem-cell replacement strategy as programs move toward clinical development.
Additional Funding For NCEL-101The financing provides capital for NCEL-101 development, working capital and corporate needs, helping fund IND-enabling activities. The 60-day issuance standstill also temporarily limits additional equity-linked dilution.
Bears Say
No Operating RevenueWithout commercial revenue, NewcelX remains dependent on investors and future product success rather than internally generated resources. This limits financial resilience and leaves execution of clinical programs central to long-term viability.
Persistent Cash BurnOngoing cash consumption means the company cannot currently fund operations organically. Continued development will likely require further financing, creating exposure to dilution, funding delays and changing investor appetite.
Deep Accumulated LossesThe substantial loss base reflects a long period without sustainable profitability and reduces financial flexibility. Combined with recurring annual losses, it increases dependence on external capital while NewcelX advances uncommercialized therapies.
NewcelX News
NCEL FAQ
What was NewcelX’s price range in the past 12 months?
NewcelX lowest stock price was $1.83 and its highest was $26.90 in the past 12 months.
What is NewcelX’s market cap?
NewcelX’s market cap is $17.44M.
When is NewcelX’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NewcelX’s earnings last quarter?
Currently, no data Available
Is NewcelX overvalued?
According to Wall Street analysts NewcelX’s price is currently Undervalued.
Does NewcelX pay dividends?
NewcelX does not currently pay dividends.
What is NewcelX’s EPS estimate?
NewcelX’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NewcelX have?
NewcelX has 5,345,184 shares outstanding.
What happened to NewcelX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NewcelX?
Currently, no hedge funds are holding shares in NCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NewcelX
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
NCEL Stock 12 Month Forecast
Average Price Target
$23.00
▲(605.52% Upside)